Comparative Pharmacology
Head-to-head clinical analysis: UBRELVY versus UBROGEPANT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: UBRELVY versus UBROGEPANT.
UBRELVY vs UBROGEPANT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Calcitonin gene-related peptide (CGRP) receptor antagonist; blocks CGRP-mediated vasodilation and nociception.
Ubrogepant is a calcitonin gene-related peptide (CGRP) receptor antagonist. It binds to CGRP receptors, blocking the vasodilatory and pro-inflammatory effects of CGRP, thereby aborting migraine attacks without causing vasoconstriction.
100 mg orally once, may repeat once after at least 2 hours if needed; maximum 200 mg per 24 hours.
50 mg or 100 mg orally once daily as needed for acute treatment of migraine attacks; maximum daily dose: 200 mg. Not for prophylactic use.
None Documented
None Documented
Terminal elimination half-life is approximately 50 hours, supporting once-daily dosing.
Terminal elimination half-life is ~5-7 hours, supporting twice-daily dosing for migraine prevention.
Primarily hepatic metabolism via CYP3A4, with 42% of dose excreted in feces (6% unchanged) and 26% in urine (1% unchanged).
Primarily eliminated via biliary/fecal excretion (approximately 70% of dose recovered in feces) with ~30% renal excretion (mostly as unchanged drug).
Category C
Category C
CGRP Antagonist
CGRP Antagonist